LifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PT

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is one of the Best Small-Cap Growth Stocks to Buy Right Now. On August 12,  Sam Slutsky from LifeSci Capital maintained a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $74.

The analyst noted that the company has shown progress in its pipeline. It is advancing its Barzolvolimab program, focusing on treating chronic spontaneous urticaria. The Phase 3 trials for this study are expected to finish enrollment in summer 2026. Moreover, the recent Phase 2 study showed promising results with many patients achieving complete responses and good disease control. Slutsky noted that the company has managed its cash burn efficiently and has a clear strategy, which justifies the Buy rating.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a clinical-stage biotech company focused on developing antibody-based therapies. The company targets mast cell-related diseases, including severe inflammatory and allergic conditions.

While we acknowledge the potential of CLDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.